Back to User profile » Dr Qi Yu
Papers published by Dr Qi Yu:
Real-World Efficacy and Safety of Adalimumab Biosimilar (HS016) in Biologic-Naïve Patients with Perianal Fistulizing Crohn’s Disease: A Prospective, Single-Arm, Observational Study
Yu Q, Cheng Y, Wang H, Fang L, Chen Y, Zhang X, Li J, Fu X, Li J, Zhu L
Drug Design, Development and Therapy 2026, 20:574904
Published Date: 30 March 2026
Effect of Machine Learning on Risk Stratification for Antiretroviral Treatment Failure in People Living with HIV
Zhang W, Ren L, Yang K, Yan J, Yu Q, Qi S, Ruan H, Zhao D, Ruan L
Infection and Drug Resistance 2025, 18:1761-1772
Published Date: 9 April 2025
Nutritional Indices Predict All Cause Mortality in Patients with Multi-/Rifampicin-Drug Resistant Tuberculosis
Hu S, Guo J, Chen Z, Gong F, Yu Q
Infection and Drug Resistance 2024, 17:3253-3263
Published Date: 30 July 2024
A Novel Inflammatory Indicator for Tuberculosis-Associated Obstructive Pulmonary Disease (TOPD): The Systemic Inflammatory Response Index (SIRI)
Hu S, Yu Q, Liu F, Gong F
Journal of Inflammation Research 2024, 17:4219-4228
Published Date: 2 July 2024
Construction and Validation of a Diagnostic Scoring System for Predicting Active Pulmonary Tuberculosis in Patients with Positive T-SPOT Based on Indicators Associated with Coagulation and Inflammation: A Retrospective Cross-Sectional Study
Yu Q, Guo J, Gong F
Infection and Drug Resistance 2023, 16:5755-5764
Published Date: 31 August 2023
A Scoring System Based on Laboratory Parameters and Clinical Features to Predict Unfavorable Treatment Outcomes in Multidrug- and Rifampicin-Resistant Tuberculosis Patients
Yan J, Luo H, Nie Q, Hu S, Yu Q, Wang X
Infection and Drug Resistance 2023, 16:225-237
Published Date: 10 January 2023
The Novel Predictive Biomarkers for Type 2 Diabetes Mellitus in Active Pulmonary Tuberculosis Patients
Yu Q, Weng W, Luo H, Yan J, Zhao X
Infection and Drug Resistance 2022, 15:4529-4539
Published Date: 13 August 2022